Background
Methods
Study design
Patient population
Randomization
Study outcomes
Patient-reported outcomes
Statistical analysis
Results
Study population
Placebo (n = 100) | Eptinezumab 100 mg (n = 90) | Total (N = 190) | |
---|---|---|---|
Sex, n (%) | |||
Male | 18 (18.0) | 24 (26.7) | 42 (22.1) |
Female | 82 (82.0) | 66 (73.3) | 148 (77.9) |
Age, median (interquartile range) | 43.5 (35–52) | 43.5 (37–54) | 43.5 (35–52) |
Region, n (%) | |||
Asia | 81 (81.0) | 74 (82.2) | 155 (81.6) |
Europe | 19 (19.0) | 16 (17.8) | 35 (18.4) |
Baseline characteristics, days (SD) | |||
Mean MMDs | 19.7 (3.8) | 19.5 (3.6) | 19.6 (3.7) |
Mean MHDs | 20.9 (3.3) | 20.6 (2.9) | 20.8 (3.2) |
Mean AHM use (days) | 18.9 (4.5) | 19.2 (4.6) | 19.1 (4.6) |
Baseline mean MMDs with use of AHM | 19.2 (4.0) | 18.9 (3.8) | 19.1 (3.9) |
Previous preventive treatment failures, n (%) | |||
Amitriptyline | 15 (15.0) | 12 (13.3) | 27 (14.2) |
Botulinum toxin A | 13 (13.0) | 10 (11.1) | 23 (12.1) |
Candesartan | 2 (2.0) | 0 (0.0) | 2 (1.1) |
Divalproex | 1 (1.0) | 1 (1.1) | 2 (1.1) |
Flunarizine | 20 (20.0) | 15 (16.7) | 35 (18.4) |
Metoprolol | 4 (4.0) | 3 (3.3) | 7 (3.7) |
Propranolol | 10 (10.0) | 9 (10.0) | 19 (10.0) |
Topiramate | 20 (20.0) | 16 (17.8) | 36 (18.9) |
Valproate | 3 (3.0) | 3 (3.3) | 6 (3.2) |
Other | 24 (24.0) | 18 (20.0) | 42 (22.1) |
Efficacy outcomes
Placebo (n = 100) | Eptinezumab 100 mg (n = 90) | |
---|---|---|
Primary endpoint | ||
Change from baseline in MMDs (Weeks 1–12; FAS) | ||
Change in mean from baseline (SE) | -5.9 (0.68) | -7.2 (0.73) |
Difference from placebo (95% CI) | -1.2 (-2.9 to 0.4) | |
p-value vs placebo | 0.1484 | |
Key secondary endpoints | ||
Changes from baseline in MMDs with AHM (Weeks 1–12) | ||
Change in mean from baseline (SE) | -6.2 (0.69) | -7.5 (0.73) |
Difference from placebo (95% CI) | -1.3 (-3.0 to 0.4) | |
p-value vs placebo | 0.1363 | |
≥ 50% reduction from baseline in MMDs (Weeks 1–12), n/N (%) | 24/100 (24.0) | 28/90 (31.1) |
Difference to placebo (%) | 7.1 | |
Odds ratio vs placebo (95% CI) | 1.45 (0.76 to 2.77) | |
p-value vs placebo | 0.2563 | |
Migraine rate on the day after dosing (Day 1) | ||
Baseline, n (%) | 100 (70.5) | 90 (69.5) |
Day 1, n (%) | 99 (59.2) | 90 (44.2) |
p-value vs placebo | 0.0315 | |
≥ 75% reduction from baseline in MMDs (Weeks 1–4), n/N (%) | 1/99 (1.0) | 16/90 (17.8) |
Difference to placebo (%) | 16.8 | |
Odds ratio vs placebo (95% CI) | 20.74 (4.07 to 378.98) | |
p-value vs placebo | < 0.0001 | |
Change from baseline in the number of MHDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.9 (0.67) | -7.1 (0.70) |
Difference from placebo (95% CI) | -1.2 (-2.9 to 0.5) | |
p-value vs placebo | 0.1516 | |
≥ 75% reduction from baseline in MMDs (Weeks 1–12), n/N (%) | 2/100 (2.0) | 15/90 (16.7) |
Difference to placebo (%) | 14.7 | |
Odds ratio vs placebo (95% CI) | 9.78 (2.64 to 63.44) | |
p-value vs placebo | 0.0002 |
Patient-reported outcomes
Subgroup analyses: efficacy outcomes
Placebo (n = 72) | Eptinezumab 100 mg (n = 65) | |
---|---|---|
Primary endpoint | ||
Change from baseline in MMDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.6 (0.71) | -7.1 (0.75) |
Difference from placebo (95% CI) | -1.4 (-3.5 to 0.6) | |
p-value vs placebo | 0.1584 | |
Key secondary endpoints | ||
Changes from baseline in MMDs with AHM (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.8 (0.72) | -7.4 (0.76) |
Difference from placebo (95% CI) | -1.6 (-3.7 to 0.4) | |
p-value vs placebo | 0.1216 | |
≥ 50% reduction from baseline in MMDs (Weeks 1–12), n/N (%) | 16/72 (22.2) | 21/65 (32.3) |
Difference to placebo (%) | 10.1 | |
Odds ratio vs placebo (95% CI) | 1.75 (0.81 to 3.87) | |
p-value vs placebo | 0.1563 | |
Migraine rate on the day after dosing (Day 1) | ||
Baseline, n (%) | 72 (69.0) | 65 (70.9) |
Day 1, n (%) | 71 (57.1) | 65 (42.0) |
p-value vs placebo | 0.0612 | |
≥ 75% reduction from baseline in MMDs (Weeks 1–4), n/N (%) | 1/71 (1.4) | 13/65 (20.0) |
Difference to placebo (%) | 18.6 | |
Odds ratio vs placebo (95% CI) | 20.12 (3.68 to 378.87) | |
p-value vs placebo | < .0001 | |
Change from baseline in the number of MHDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.6 (0.70) | -7.0 (0.74) |
Difference from placebo (95% CI) | -1.5 (-3.5 to 0.6) | |
p-value vs placebo | 0.1548 | |
≥ 75% reduction from baseline in MMDs (Weeks 1–12), n/N (%) | 1/72 (1.4) | 12/65 (18.5) |
Difference to placebo (%) | 17.1 | |
Odds ratio vs placebo (95% CI) | 19.04 (3.44 to 359.04) | |
p-value vs placebo | 0.0001 |
Placebo (n = 19) | Eptinezumab 100 mg (n = 16) | |
---|---|---|
Primary endpoint | ||
Change from baseline in MMDs (Weeks 1–12) | ||
Change in mean from baseline (SE) | -5.3 (1.48) | -8.6 (1.73) |
Difference from placebo (95% CI) | -3.3 (-8.0 to 1.5) | |
p-value vs placebo | 0.1713 |
Safety and tolerability
Placebo (n = 100) | Eptinezumab 100 mg (n = 93) | |
---|---|---|
Patients with TEAEs, n (%) | 34 (34.0) | 38 (40.9) |
Total number of TEAEs | 59 | 74 |
TEAEs occurring in ≥ 2% of patients, n (%) | 15 (15.0) | 18 (19.4) |
Upper respiratory tract infection | 2 (2.0) | 3 (3.2) |
Dermatitis atopic | 0 (0) | 2 (2.2) |
Diarrhea | 1 (1.0) | 2 (2.2) |
Dizziness | 2 (2.0) | 2 (2.2) |
Glycosylated haemoglobin increased | 1 (1.0) | 2 (2.2) |
Muscle spasms | 0 (0.0) | 2 (2.2) |
Nasopharyngitis | 0 (0.0) | 2 (2.2) |
Nausea | 2 (2.0) | 2 (2.2) |
Proteinuria | 0 (0.0) | 2 (2.2) |
Urinary tract infection | 1 (1.0) | 2 (2.2) |
Influenza-like illness | 2 (2.0) | 1 (1.1) |
Fatigue | 4 (4.0) | 0 (0.0) |
Urinary tract infection, bacterial | 4 (4.0) | 0 (0.0) |
Patients with SAEs, n (%) | 0 (0.0) | 2 (2.2) |
Total number of SAEs | 0 | 2 |
Patients with TEAEs leading to infusion interruption/termination, n (%) | 0 (0.0) | 0 (0.0) |
Total number of TEAEs leading to study drug infusion interruption/termination | 0 | 0 |
Patients with TEAEs leading to withdrawal, n (%) | 1 (1.0%) | 2 (2.2%) |
Total number of TEAEs leading to withdrawal | 1 | 2 |
Deaths, n (%) | 0 (0.0) | 0 (0.0) |
Placebo–eptinezumab 100 mg (n = 81) | Eptinezumab 100 mg–eptinezumab 100 mg (n = 81) | |
---|---|---|
Patients with TEAEs, n (%) | 38 (46.9) | 34 (42.0) |
Total number of TEAEs | 71 | 74 |
TEAEs occurring in ≥ 2% of patients, n (%) | ||
Migraine | 1 (1.2) | 5 (6.2) |
Covid-19 | 3 (3.7) | 3 (3.7) |
Pyrexia | 0 (0.0) | 3 (3.7) |
Urinary tract infection | 0 (0.0) | 3 (3.7) |
Bronchitis | 1 (1.2) | 2 (2.5) |
Glucose tolerance impaired | 0 (0.0) | 2 (2.5) |
Headache | 0 (0.0) | 2 (2.5) |
Myalgia | 1 (1.2) | 2 (2.5) |
Pharyngotonsillitis | 0 (0.0) | 2 (2.5) |
Dizziness | 3 (3.7) | 1 (1.2) |
Abdominal pain upper | 2 (2.5) | 0 (0.0) |
Diarrhea | 2 (2.5) | 0 (0.0) |
Fatigue | 2 (2.5) | 0 (0.0) |
Hyperlipidemia | 3 (3.7) | 0 (0.0) |
Proteinuria | 2 (2.5) | 0 (0.0) |
Upper respiratory tract infection | 11 (13.6) | 0 (0.0) |
Patients with SAEs, n (%) | 0 (0.0) | 4 (4.9) |
Total number of SAEs | 0 | 7 |
Patients with TEAEs leading to infusion interruption/termination, n (%) | 0 (0.0) | 0 (0.0) |
Total number of TEAEs leading to study drug infusion interruption/termination | 0 | 0 |
Patients with TEAEs leading to withdrawal, n (%) | 1 (1.2) | 1 (1.2) |
Total number of TEAEs leading to withdrawal | 1 | 1 |
Deaths, n (%) | 0 (0.0) | 0 (0.0) |